Terminated PHASE1 INTERVENTIONAL 2-arm NCT03309358

A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis

A Multiple-Site, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study to Assess the Safety and Tolerability of Inhaled SNSP113 in Healthy Male Subjects (Part A) and Subjects With Stable Cystic Fibrosis (Part B)

Sponsor: Synspira, Inc.

Conditions Antibiotic Resistant Infection Burkholderia Cepacia Infection Burkholderia Infections Cystic Fibrosis Cystic Fibrosis Lung Cystic Fibrosis Pulmonary Exacerbation Cystic Fibrosis With Exacerbation Lung Diseases Lung Infection Lung Infection Pseudomonal Lung Inflammation Lung; Infection, Atypical Mycobacterium Multi-antibiotic Resistance Pulmonary Disease Pulmonary Inflammation Respiratory Tract Disease

Interventions Inhaled Placebo Inhaled SNSP113

Updated 5 times since 2017 Last updated: May 23, 2018 Started: Sep 28, 2017 Primary completion: Dec 18, 2017 Completion: Dec 18, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Successful completion of Part A. Company decision to end early.

A PHASE1 clinical study on Antibiotic Resistant Infection and Burkholderia Cepacia Infection, this trial is terminated or withdrawn. The trial is conducted by Synspira, Inc. and has accumulated 5 data snapshots since 2017. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1

Status: Recruiting → Terminated
Oct 2017 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

Sep 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Synspira, Inc.

Data source: Synspira, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Belfast, United Kingdom
• London, United Kingdom